Business Context and Reporting Period
This Form 6-K filing by GSK plc, a global biopharma company, was issued on August 3, 2026. The report covers the month of August 2026 and serves as a notification to the market regarding the company's total voting rights as of July 31, 2026, in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance notification rather than a financial performance report.
| Metric | Value |
|---|---|
| Issued Share Capital (as of July 31, 2026) | 4,316,292,310 Ordinary Shares (31 1/4 pence each) |
| Treasury Shares | 270,881,064 |
| Total Voting Rights | 4,045,411,246 |
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period regarding financial performance or operational metrics. The document focuses solely on the current count of voting rights.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on future performance, risks, contingencies, or unusual items. The document includes a standard corporate description stating GSK's purpose is to unite science, technology, and talent to get ahead of disease together.
Investor Verification Checklist
- Verify the total voting rights denominator (4,045,411,246) for calculating disclosure thresholds under FCA rules.
- Confirm the number of treasury shares held (270,881,064) to understand the difference between issued capital and voting rights.
- Check the company secretary contact (company.secretary@gsk.com) for submitting interest notifications.